ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DVAX Dynavax Technologies Corp

11.50
-0.18 (-1.54%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Dynavax Technologies Corp NASDAQ:DVAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.18 -1.54% 11.50 11.50 11.96 11.83 11.52 11.70 1,760,401 22:07:05

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Dynavax Technologies Corporation

18/11/2016 11:10pm

Business Wire


Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Dynavax Technologies Charts.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Dynavax Technologies Corporation securities (NASDAQ:DVAX) from March 10, 2014 through November 11, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Dynavax investors under the federal securities laws.

To join the Dynavax class action, go to http://rosenlegal.com/cases-950.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) there were significant adverse events associated with Dynavax’s HEPLISAV-B product, including an imbalance in the number of cardiac events during use; (2) consequently, a commercial product launch of HEPLISAV-B was less imminent than Dynavax had led investors to believe; and (3) as a result, Dynavax’s public statements were materially false and misleading at all relevant times.. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-950.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

The Rosen Law Firm, P.A.Laurence Rosen, Esq.Phillip Kim, Esq.Kevin Chan, Esq.275 Madison Avenue, 34th FloorNew York, NY 10016Tel: 212-686-1060Toll Free: 866-767-3653Fax: 212-202-3827lrosen@rosenlegal.compkim@rosenlegal.comkchan@rosenlegal.comwww.rosenlegal.com

1 Year Dynavax Technologies Chart

1 Year Dynavax Technologies Chart

1 Month Dynavax Technologies Chart

1 Month Dynavax Technologies Chart

Your Recent History

Delayed Upgrade Clock